NAFDAC Guidelines on Variation to a Registered Pharmaceutical Product
Guideline · Health
Guidelines classify and manage changes to registered pharmaceutical products, from minor to major modifications. They target regulated entities, NAFDAC teams, and industry stakeholders. This ensures that product safety, quality, and efficacy are maintained.
NAFDAC Guidelines on Variation to a Registered Pharmaceutical Product
What Is This Policy?
Guidelines classifying and managing post-registration changes (variations) to approved pharmaceutical products, from minor administrative changes to major quality or safety modifications.
Who Does It Target?
Manufacturers and importers of registered pharmaceutical products seeking to amend approved formulations, manufacturing processes, or product labelling; regulatory affairs departments in pharmaceutical companies; NAFDAC's post-market surveillance and variation assessment teams
NAFDAC teams Industry stakeholders
What Does It Aim to Achieve?
Ensure that changes to registered products are properly evaluated and do not compromise safety, quality, or efficacy.
Key Features
Variation Categories: Type I (minor), Type II (major), and notification-only changes Documentation: Supporting data required for each variation type Approval Timeline: Different review timelines based on variation category Implementation: Rules on when changes may be implemented relative to approval
Current Status
Rollout Stage: Active Coverage: All applicable entities Lead Agency: NAFDAC
How to Access
Regulated entities must comply. Classify the proposed change per variation guidelines Prepare and submit the variation application with supporting data Implement changes only after NAFDAC approval where required
Official Resources
Website: nafdac.gov.ng Contact: NAFDAC, Abuja
Legal Framework
Issued under the National Agency for Food and Drug Administration and Control Act 1993 (as amended). Operates alongside the Food and Drugs Act Cap F32 LFN 2004, the Pharmacists Council of Nigeria Act, the ICH Good Manufacturing Practice guidelines, WHO prequalification standards, and the Falsified Medicines guidelines adopted by Nigeria. Draws on ICH Q10 Pharmaceutical Quality Systems guidelines and WHO guidelines on variations to marketing authorisations for pharmaceutical products.